At ceremonial / low-dose (1-2 shells of traditional aqueous prep, ~70-150 mg total kavalactones):

• Mild facial numbness (kavain anesthetic effect on oral mucosa — diagnostic)
• Onset 10-20 min; peak 30-60 min; total experience 2-4 hr
• Calm without sedation; "the worry leaves the body before it leaves the mind"
• Mildly improved sociability — comparable to a single drink of wine for many users, minus the disinhibition cliff
• Music and sensory perception subtly enhanced
• No cognitive impairment at this dose tier — Pacific elders conduct extensive ritual oratory under kava

At anxiolytic / mid-dose (3-4 shells, ~150-250 mg kavalactones; or 100-200 mg standardized extract):

• Pronounced anxiolysis — phenomenologically distinct from benzodiazepines (less "blanketing," more "subtracting" the anxious affect)
• Mild muscle relaxation
• Slight motor slowing (do not drive)
• Sleep onset improved if used 30-60 min pre-bed; no morning grogginess at this dose
• Some users describe a "warm" body sensation and improved emotional contact with others

At high / "bender" dose (5+ shells, or repeated daily sessions):

• Pronounced sedation, ataxia, and motor incoordination
• "Kava drunk" — long, slow euphoria with disinhibition lower than alcohol but real
• Next-day "kava hangover" especially with tudei cultivars — lethargy, mild headache, photophobia
• Chronic heavy use: kava dermopathy (scaly yellowish skin), transient LFT elevation, weight loss, occasional apathy

Subjective ceiling: Kava has a relatively flat dose-response above ~250-300 mg kavalactones — additional intake produces more nausea than additional anxiolysis. This is part of why traditional preparations are self-limiting (you stop drinking before you can hurt yourself with the kavalactones alone).

• Pharmacodynamic tolerance develops with daily use over 2-4 weeks — the anxiolytic effect attenuates, and users escalate dose. This is real but slower and less dramatic than the phenibut/benzodiazepine tolerance curve. The cross-tolerance pattern is partial with benzodiazepines and alcohol.
• Dependence pharmacology: mild compared to benzodiazepines or phenibut, but not absent. Heavy daily kava drinkers report withdrawal symptoms on cessation — anxiety rebound, sleep disruption, mild dysphoria. Severity is closer to caffeine or chronic alcohol withdrawal of moderate intensity than to benzodiazepine withdrawal. No documented seizures from kava withdrawal alone.
• "Kava bender": consuming many shells in a single ceremonial or recreational session produces prolonged sedation, kava hangover (especially with tudei), and is the dose-pattern most associated with acute LFT elevation. Better to space sessions.
• Recommended cycling: ≤4-8 weeks regular use, then ≥2-4 weeks washout. Many users adopt "weekend-only" or "twice-weekly" patterns — this works pharmacologically (kavalactones do not bioaccumulate significantly) and helps cap hepatic exposure.
• Reset protocol on heavy use: taper over 1-2 weeks; full nervous-system normalization within 4-8 weeks. LFT recheck at 4 weeks post-cessation if any prior elevation.

Synergistic / useful co-administration

• L-theanine (200-400 mg): Additive anxiolysis at sub-sedating doses. Reduces the dose of kava needed and lowers hepatic load. Common pairing in r/Kava harm-reduction protocols.
• Magnesium glycinate (200-400 mg): Muscle relaxation + GABAergic potentiation; no hepatic interaction. Often paired for sleep-onset use.
• Glycine (3 g) + apigenin (50 mg): Sleep-stack synergy without hepatic burden.
• Lemon balm (Melissa officinalis): Mild GABA-transaminase inhibitor; anxiolytic synergy at low doses. Hepatically clean.

Avoid stacking with

• Alcohol: Synergistic hepatotoxicity (well-documented); multiplicative CNS depression; cross-tolerance accelerates kava tolerance buildup. The single most important "don't" in the kava interaction landscape.
• Acetaminophen (paracetamol): Both deplete hepatic glutathione; well-described case reports of accelerated hepatic injury when co-administered. Avoid for at least 24 hr around any kava session.
• Benzodiazepines, Z-drugs, baclofen, gabapentin, phenibut: Additive CNS depression; redundant target.
• Opioids: Multiplicative respiratory depression risk.
• SSRIs / SNRIs: Theoretical interaction via MAO-B + monoamine reuptake; case reports of serotonin-syndrome-like presentations. Monitor closely if combined; better to avoid in early SSRI titration.
• MAOIs (selegiline, moclobemide, phenelzine): Theoretical synergy with kava's weak MAO-B inhibition; avoid.
• CYP450 substrates with narrow therapeutic index — see Drug interactions.

Neutral / safe co-administration

• Most multivitamins, omega-3, vitamin D, ashwagandha, rhodiola: No clinically significant interaction at standard doses.
• Caffeine: Antagonistic (kava sedation vs caffeine arousal); not dangerous but reduces utility of both. Dylan's no-caffeine baseline sidesteps this entirely.

Kavalactones inhibit a wide swath of hepatic CYP450 isoforms, which is the single largest pharmacokinetic interaction concern outside the hepatotoxicity question itself:

• CYP1A2: moderate inhibition — caffeine, theophylline, duloxetine, clozapine, melatonin, ramelteon, ropinirole
• CYP2C9: strong inhibition — warfarin, NSAIDs (ibuprofen, naproxen), phenytoin, losartan
• CYP2C19: strong inhibition — PPIs (omeprazole, esomeprazole), citalopram, clopidogrel (activation reduced), diazepam
• CYP2D6: moderate inhibition — codeine, tramadol, oxycodone (activation altered), TCAs, many SSRIs, beta-blockers
• CYP3A4: moderate-to-strong inhibition — statins, calcium channel blockers, midazolam, alprazolam, oral contraceptives, immunosuppressants, many SSRIs, modafinil/armodafinil (modafinil is also a 3A4 inducer — net effect unpredictable, avoid combination), tadalafil/sildenafil

Practical takeaways for Dylan:

• No combination with modafinil if modafinil enters the stack later — overlapping 3A4 effects produce unpredictable AUC shifts on both sides.
• No combination with peptides metabolized via 3A4 (some BPC-157 metabolites, certain semax/selank conjugates) — wait at least 24 hr between dosing.
• No NSAIDs the day of kava use — both training-acute ibuprofen and kava run through 2C9; additive bleeding/GI risk and altered NSAID clearance.
• No oral contraceptive interaction concern for Dylan personally but relevant for any female user — kava can reduce OC efficacy via 3A4.

• CYP2D6 poor metabolizers: Likely amplified kava effect and amplified interactions with 2D6-metabolized comedications. Dylan should pull his CYP2D6 phenotype from the 23andMe + bloodwork phase (June 2026) before any sustained kava use.
• **CYP1A2 fast metabolizers (rs762551 1F/1F): Faster clearance of kavain and methysticin; subjective effect may feel "thin" or short. May tolerate slightly higher dose, but also clear hepatotoxic metabolites faster.
• HLA-B*57:01 and HLA-DR variants: Implicated in idiosyncratic drug-induced liver injury for several drugs (abacavir, flucloxacillin); a small case-cohort study suggested HLA association with kava hepatotoxicity but this is not yet actionable.
• GSTM1 null genotype: Reduced glutathione conjugation capacity; theoretically elevates kava hepatotoxicity risk via reduced clearance of reactive metabolites. Not yet clinically actionable but worth flagging if 23andMe surfaces the variant.
• GABA-A subunit polymorphisms (GABRA2, GABRB1): May modulate subjective response intensity — anecdotal pattern in r/Kava and r/Nootropics but no PGx study has formalized this for kava specifically.

Bottom line for Dylan: Pull CYP2D6, CYP2C9, CYP2C19, CYP3A4, GSTM1, and HLA variants from the June 2026 genetics pass before any extended kava protocol. Kava is one of the compounds where PGx-mediated risk stratification is genuinely informative.

Sourcing-difficulty rating: easy — quality noble water-extracted root is widely available from US-shipping vendors, with COA-backed cultivar labeling becoming standard.

Key sourcing rules:

1. Noble cultivar only (named: Borogu, Mahakea, Mo'i, Melomelo, etc.)
2. Root only — no peelings, no leaf, no stem (where flavokavain B concentrates)
3. Water extraction only for any extract product
4. Lab-tested chemotype if possible (e.g., chemotype 246531 is classic anxiolytic-noble)

• Baseline (pre-use): ALT, AST, GGT, total + direct bilirubin, alkaline phosphatase, albumin. INR if any anticoagulant overlap.
• At 4 weeks of regular use (≥2× per week): Repeat ALT/AST/GGT. Discontinue if ALT or AST >2× baseline or >50% above upper limit of normal.
• At 8 weeks of regular use: Full LFT recheck + bilirubin. Mandatory washout if approaching 8-week regular-use cap.
• Subjective tracking: Daily anxiety VAS (0-10), sleep-onset latency (minutes), morning grogginess (0-10), motor coordination self-rating. Useful for catching the tolerance plateau early.
• For Dylan specifically (per V4 biomarker integration): Add to the quarterly bloodwork panel during any kava-using quarter — kava-specific LFT delta is more important than the absolute number.
• Dermatologic: Self-check for kava dermopathy at week 4 and week 8 — yellowish, scaly skin on shins/forearms is the classic presentation, fully reversible on cessation.